Who is sponsoring NCT03502824?

NCT03502824 is sponsored by Organogenesis.

What drugs are being tested in NCT03502824?

Interventions in NCT03502824: PuraPly® Antimicrobial Wound Matrix, SOC for Pressure Ulcers.

What condition does NCT03502824 study?

NCT03502824 studies Chronic Pressure Ulcers.

Is NCT03502824 still recruiting?

NCT03502824 is currently terminated. Last updated 22 September 2021.

Last reviewed 2021-09-22 · How we verify

NCT03502824

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

Terminated NA Last updated 22 September 2021

What this trial tests

NA trial testing PuraPly® Antimicrobial Wound Matrix in Chronic Pressure Ulcers in 40 participants. Terminated before completion.

Timeline

1 May 2018

Primary endpoint
15 September 2021

15 September 2021

Quick facts

Lead sponsor	Organogenesis
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	40
Start date	1 May 2018
Primary completion	15 September 2021
Estimated completion	15 September 2021
Sites	2 locations across United States

Drugs / interventions tested

PuraPly® Antimicrobial Wound Matrix
SOC for Pressure Ulcers

Conditions studied

Chronic Pressure Ulcers — all drugs for Chronic Pressure Ulcers →

Sponsor

Organogenesis — full company profile →

Who can join

Adults 18 to 99, any sex, with Chronic Pressure Ulcers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multi-center, randomized, controlled clinical study Of PuraPly® AM and standard of care (SOC) compared to SOC alone for the management of Stage II-IV pressure ulcers located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Organogenesis trials

Trials by the same sponsor.

NCT06618612 — A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguan · NA · recruiting
NCT06000410 — A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee · Phase 3 · completed
NCT04636229 — Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee · Phase 3 · completed
NCT03205436 — Affinity Prospective Diabetic Foot Trial Crossover Group · NA · completed
NCT03286452 — The RESPOND Registry · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03502824 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Organogenesis
Last refreshed: 22 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03502824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing